BioMarin Pharmaceutical $BMRN

Health Care · NASDAQ

$60.41
-1.01 (-1.64%)
As of Nov 20, 2026, 4:05 PM EST · cached
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Aug 31, 2026, the first target we tracked for BMRN.

BioMarin Pharmaceutical (BMRN) is trading down at $60.41 (-1.64%) on NASDAQ, as of the latest quote. It is a Russell 1000 constituent in the Health Care sector.

Analyst price targets on BMRN

Current price targets from 2 firms average $95, ranging from $66 to $124 — 57% above the current $60.4. Each is tracked to its date and scored the same way a member's call is.

2 targets, newest first. Open a row for its source and scoring.

DateNov 3, 2026 FirmStifel RatingHold · lowers Targetat $55.7 · $66 +19% Horizonby Nov 2027 StatusOpen

Entry price $55.7, the close nearest Nov 3, 2026, when the target was reported; the target is +19% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Nov 2027.

Scoring Open: judged on the close on Nov 3, 2027.

Source Stifel cuts BioMarin stock price target to $66 on growth concerns Investing.com · Nov 3, 2026 · opens the publisher's site
Stifel lowered its price target on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to $66 from $70 while maintaining a Hold rating on the stock.
DateAug 31, 2026 FirmMorgan Stanley RatingOverweight · reiterates Targetat $65.2 · $124 +90% Horizonby Aug 2027 StatusOpen

Entry price $65.2, the close nearest Aug 31, 2026, when the target was reported; the target is +90% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Aug 2027.

Scoring Open: judged on the close on Aug 31, 2027.

Source Morgan Stanley reiterates BioMarin stock rating on settlement value Investing.com · Aug 31, 2026 · opens the publisher's site
Morgan Stanley reiterated an Overweight stock rating on BioMarin Pharmaceutical Inc. with a price target of $124.00, following a settlement agreement with Ascendis.

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

BioMarin Pharmaceutical revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)
$3.22B$1.30B−$630.2MFY2016 revenue: $1.12BFY2016 net income: −$630.2M · Net margin −56.4%'16FY2017 revenue: $1.31BFY2017 net income: −$117.0M · Net margin −8.9%'17FY2018 revenue: $1.49BFY2018 net income: −$77.2M · Net margin −5.2%'18FY2019 revenue: $1.70BFY2019 net income: −$23.8M · Net margin −1.4%'19FY2020 revenue: $1.86BFY2020 net income: $854.0M · Net margin 45.9%'20FY2021 revenue: $1.85BFY2021 net income: −$64.1M · Net margin −3.5%'21FY2022 revenue: $2.10BFY2022 net income: $141.6M · Net margin 6.8%'22FY2023 revenue: $2.42BFY2023 net income: $167.6M · Net margin 6.9%'23FY2024 revenue: $2.85BFY2024 net income: $426.9M · Net margin 15.0%'24FY2025 revenue: $3.22BFY2025 net income: $348.9M · Net margin 10.8%'25−19.6%0%25%50%75%100%FY2016 net margin: −56.4% (off the scale, which stops at −19.6%)FY2017 net margin: −8.9%FY2018 net margin: −5.2%FY2019 net margin: −1.4%FY2020 net margin: 45.9%FY2021 net margin: −3.5%FY2022 net margin: 6.8%FY2023 net margin: 6.9%FY2024 net margin: 15.0%FY2025 net margin: 10.8%
BioMarin Pharmaceutical annual financial statements
FY2016Dec 2016FY2017Dec 2017FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$1.12B$1.31B$1.49B$1.70B$1.86B$1.85B$2.10B$2.42B$2.85B$3.22B
Growth (year over year)+25.5%+17.6%+13.5%+14.3%+9.2%−0.8%+13.5%+15.4%+18.0%+12.9%
Gross profit$907.2M$1.07B$1.18B$1.34B$1.34B$1.38B$1.59B$1.89B$2.27B$2.50B
Gross margin81.2%81.6%78.9%78.9%71.8%74.5%76.0%78.0%79.7%77.7%
Operating income−$803.4M−$14.7M−$123.5M−$100.5M−$43.4M−$82.3M$161.0M$185.8M$484.2M$409.5M
Operating margin−71.9%−1.1%−8.3%−5.9%−2.3%−4.5%7.7%7.7%17.0%12.7%
Net income−$630.2M−$117.0M−$77.2M−$23.8M$854.0M−$64.1M$141.6M$167.6M$426.9M$348.9M
Net margin−56.4%−8.9%−5.2%−1.4%45.9%−3.5%6.8%6.9%15.0%10.8%
EPS (diluted)−$3.81−$0.67−$0.44−$0.13$4.50−$0.35$0.75$0.87$2.21$1.80
Balance sheet
Cash and equivalents$408.3M$598.0M$494.0M$437.4M$649.2M$587.3M$724.5M$755.1M$942.8M$1.31B
Total assets$4.02B$4.63B$4.43B$4.69B$5.85B$6.00B$6.38B$6.84B$6.99B$7.59B
Total liabilities$1.26B$1.82B$1.46B$1.57B$1.74B$1.74B$1.77B$1.89B$1.33B$1.51B
Long-term debt—————————$597.2M
Shareholders' equity$2.77B$2.81B$2.97B$3.12B$4.10B$4.27B$4.60B$4.95B$5.66B$6.09B
Cash flow
Operating cash flow−$227.8M−$8.76M$20.2M$48.3M$85.4M$304.5M$175.9M$159.3M$572.8M$828.0M
Capital expenditure$148.4M$199.2M$144.6M$145.0M$114.3M$95.6M$121.0M$96.7M$85.4M$103.0M
Free cash flow−$376.2M−$208.0M−$124.4M−$96.8M−$28.9M$209.0M$54.9M$62.6M$487.4M$725.0M
Share buybacks——$0$0$50.0M$0$0———

From BioMarin Pharmaceutical's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

BioMarin Pharmaceutical in the news

Sep 14, 2026 PR Newswire BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).

Source: Wikipedia — BioMarin Pharmaceutical

Headquarters
Novato, California From SEC filings, Oct 2026

More Health Care stocks

Browse all companies →